Understanding rare genetic clues to Alzheimer’s risk
Official title: Functionalization of rare noncoding variants as drivers of Alzheimer's disease risk
Funded at J. David Gladstone Institutes · NIH-11297870 · Data updated 2026-11-12
A research project aims to find how rare noncoding genetic changes contribute to Alzheimer's risk and why they may lead to brain degeneration.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | September 15, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $845,617 |
| NIH project number | 1R01AG093119-01A1 |
| Project ID | NIH-11297870 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with or at risk for Alzheimer’s disease who may benefit from future genetic or therapeutic advances, including those with APOE-related risk.
✕Less likely to help
People without a genetic risk profile or without interest in genetic insight into their risk may not directly benefit.
What this research studies
This project will explore rare noncoding DNA variants that might influence Alzheimer’s risk. Researchers will use advanced 3C-based methods to study how these variants affect gene regulation in brain-related cells. The goal is to connect specific rare variants to the biology of Alzheimer’s, which could uncover new targets for therapy. If successful, this work could pave the way for personalized approaches based on a patient’s genetic makeup.
Why it matters
Potential benefit: Could lead to new ways to predict risk and develop targeted therapies for Alzheimer’s disease.
How similar studies have gone: Previous studies point to a significant portion of risk being due to rare noncoding variants, but this approach is an innovative step in linking them to function.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Corces, Michael Ryan — J. David Gladstone Institutes
- Study coordinator: Corces, Michael Ryan
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.